<DOC>
	<DOCNO>NCT03085693</DOCNO>
	<brief_summary>Closure leave atrial appendage patient atrial fibrillation risk stroke increase technology lead exclusion leave atrial appendage volume blood circulation therefore protect cardioembolic strokes- It unclear volume reduction leave atrium lead change exercise capacity Quality life .</brief_summary>
	<brief_title>Impact Left Atrial Appendage Closure Physical Capacity .</brief_title>
	<detailed_description>The monocentric trial deal endocrinological change result closure leave atrial appendage internal closure device . Specially , change atrial natriuretic peptide , brain natriuretic peptide impact exercise capacity focus trial . The trial plan comer trial .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Patient indication LAA closure device Implantation Inability perform exercise testing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>